1. Gilead demonstrates transformative potential impact of antiviral innovation at CROI 2023
- Subjects
Gilead Sciences Inc. -- Innovations ,Biological products industry -- Innovations ,AIDS treatment ,International relief -- United States ,Emtricitabine -- Innovations ,Virus diseases -- Development and progression ,Business ,Chemicals, plastics and rubber industries ,Veklury (Medication) - Abstract
Gilead Sciences Inc announced on 14 Feb 2023 the upcoming presentation of new clinical and real-world data from the company's HIV, COVID-19 and viral hepatitis research and development programmes at the 30th Conference on Retroviruses and Opportunistic Infections (CROI) on 19-22 Feb 2023. Seventy abstracts, including late-breaking data, demonstrate Gilead's continued expertise and leadership in virology with a commitment to advance the next wave of scientific discovery to treat, prevent, cure and help eradicate viral diseases. Gilead is committed to continuous scientific discovery to provide solutions for the evolving needs of people affected by HIV around the world, with the goal of ending the HIV epidemic for everyone, everywhere. At CROI 2023, Gilead will share new findings on HIV treatment and prevention strategies, as well as the latest updates from the company's continued pursuit of an HIV cure. HIV treatment research and development data include proof-of-concept Phase 1b data on the safety and efficacy profile of lenacapavir in combination with investigational broadly neutralizing antibodies (bNAbs) - teropavimab and zinlirvimab - dosed twice-yearly in virologically suppressed adults for the treatment of HIV. Additionally, Gilead will present data from a preclinical in vivo assessment of a single subcutaneous administration of lenacapavir for pre-exposure prophylaxis (PrEP). Gilead will present data that reinforce the critical role Veklury (remdesivir) plays as the antiviral standard of care for the treatment of hospitalized patients with COVID-19. Real-world insights on Veklury's use will provide important, up-to-date evidence from large, hospitalized populations - including patients with immunocompromised conditions - across different periods of the pandemic and different variants of concern. Additionally, Gilead will present a new in vitro analysis that evaluates the antiviral activity of Veklury against common variants of concern, and data assessing the resistance profile of Veklury and other antiviral compounds. Gilead will present new data from the ALLIANCE trial, which is an ongoing Phase 3 trial evaluating Biktarvy (bictegravir 50 mg/emtricitabine 200 mg/tenofovir alafenamide 25 mg tablets, B/F/TAF) versus dolutegravir (50 mg, DTG) + emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg, F/TDF, DTG+F/TDF, in adults with HIV-1/HBV co-infection who are initiating treatment. The sub-analysis of Week 48 results complements the initial data presented at the 24th International AIDS Conference (AIDS 2022), with a focus on the HBV outcomes in this coinfected population. Original source: Gilead, website: http://www.gilead.com/, Copyright Gilead 2023., research and development; anti-HIV drugs; antiviral agents; bictegravir; Biktarvy; dolutegravir; emtricitabine; hepatitis B treatments; lenacapavir; monoclonal antibodies; remdesivir; respiratory disease treatments; tenofovir; tenofovir alafenamide; tenofovir disoproxil fumarate; teropavimab; therapeutic antibodies; [...]
- Published
- 2023